Acuitas AMR Gene Panel
Sep 2021
871d
Opgen, Inc. has submitted 1 FDA 510(k) premarket notifications since 2021, of which 1 received clearance as substantially equivalent to a predicate device.
The company's most frequent device categories include System, Nucleic Acid Amplification Test, Dna, Carbapenem Non-susceptible Gram Negative Organism, Colony . Use the specialty filter in the sidebar to narrow results.